Artwork

Contenido proporcionado por Gastro Broadcast. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Gastro Broadcast o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.
Player FM : aplicación de podcast
¡Desconecta con la aplicación Player FM !

Episode #49: Treating C. diff by Reducing the Associated Inflammation (research shows that it works in mice)

17:14
 
Compartir
 

Manage episode 379414484 series 3382401
Contenido proporcionado por Gastro Broadcast. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Gastro Broadcast o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.
Dr. Lisa Mathews interviews Dr. Min Dong and Dr. Meenakshi Rao of the Boston Children’s Hospital regarding new research published in Nature that shows two FDA-approved drugs can alter our body’s own immune response to treat Clostridioides difficile (C. diff) more effectively. C. diff is the leading cause of gastrointestinal infections in the United States, and existing medications don’t always work because of antibiotic resistance, the presence of more lethal strains, and a drugs’ potential to harm good gut bacteria that prevent infection. The study conducted by Dr. Dong and Dr. Rao found that two already approved medications reduced inflammation associated with C. diff infection in mice, allowing for their immune systems to mount a more productive response to the infection. Listen to Dr. Mathew, Dr. Dong, and Dr. Rao as they explore what the next steps are for this research and what it might mean for the future of treating patients with C. diff. Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC Mixed and mastered by Hayden Margolis Gastro Broadcast, Episode 49
  continue reading

67 episodios

Artwork
iconCompartir
 
Manage episode 379414484 series 3382401
Contenido proporcionado por Gastro Broadcast. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Gastro Broadcast o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.
Dr. Lisa Mathews interviews Dr. Min Dong and Dr. Meenakshi Rao of the Boston Children’s Hospital regarding new research published in Nature that shows two FDA-approved drugs can alter our body’s own immune response to treat Clostridioides difficile (C. diff) more effectively. C. diff is the leading cause of gastrointestinal infections in the United States, and existing medications don’t always work because of antibiotic resistance, the presence of more lethal strains, and a drugs’ potential to harm good gut bacteria that prevent infection. The study conducted by Dr. Dong and Dr. Rao found that two already approved medications reduced inflammation associated with C. diff infection in mice, allowing for their immune systems to mount a more productive response to the infection. Listen to Dr. Mathew, Dr. Dong, and Dr. Rao as they explore what the next steps are for this research and what it might mean for the future of treating patients with C. diff. Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC Mixed and mastered by Hayden Margolis Gastro Broadcast, Episode 49
  continue reading

67 episodios

Alla avsnitt

×
 
Loading …

Bienvenido a Player FM!

Player FM está escaneando la web en busca de podcasts de alta calidad para que los disfrutes en este momento. Es la mejor aplicación de podcast y funciona en Android, iPhone y la web. Regístrate para sincronizar suscripciones a través de dispositivos.

 

Guia de referencia rapida